{"transactions":[{"id":3524,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-09-03T22:59:19.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":877,"price":47.5,"value":41657.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":50559,"source":{"system":"sec-edgar","filing":"0000905148-26-004077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577899/000090514826004077/form4.xml","form_type":"4"}},{"id":730917,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:12:01.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003039/form4.xml","form_type":"4"}},{"id":752639,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-06-03T22:01:27.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":877,"price":29.86,"value":26187.22,"ownership":{"direct":true},"balance_after":50936,"source":{"system":"sec-edgar","filing":"0000905148-26-002807","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002807/form4.xml","form_type":"4"}},{"id":894190,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:09.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":19497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":51813,"source":{"system":"sec-edgar","filing":"0000905148-26-000956","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000956/form4.xml","form_type":"4"}},{"id":908105,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:21.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3546,"price":34.62,"value":122762.52,"ownership":{"direct":true},"balance_after":32316,"source":{"system":"sec-edgar","filing":"0000905148-26-000676","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000676/form4.xml","form_type":"4"}},{"id":919907,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2026-02-04T21:20:50.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":3968,"price":36.01,"value":142887.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":35862,"source":{"system":"sec-edgar","filing":"0000905148-26-000496","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000496/form4.xml","form_type":"4"}},{"id":1038331,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:30.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003348","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003348/form4.xml","form_type":"4"}},{"id":1197497,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:55:51.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":7850,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000905148-25-000976","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000976/form4.xml","form_type":"4"}},{"id":1197496,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:55:51.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":9,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-25-000976","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000976/form4.xml","form_type":"4"}},{"id":1280581,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2025-02-07T01:26:51.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1339,"price":21.926,"value":29358.914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":38830,"source":{"system":"sec-edgar","filing":"0000905148-25-000410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000410/form4.xml","form_type":"4"}},{"id":1280580,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2025-02-07T01:26:51.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":1448,"price":20.921,"value":30293.608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":40169,"source":{"system":"sec-edgar","filing":"0000905148-25-000410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000410/form4.xml","form_type":"4"}},{"id":1289880,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-31T23:45:12.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":14788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":14788,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14788},"source":{"system":"sec-edgar","filing":"0000905148-25-000298","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000298/form4.xml","form_type":"4"}},{"id":1289879,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2025-01-31T23:45:12.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":19717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":41617,"source":{"system":"sec-edgar","filing":"0000905148-25-000298","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000298/form4.xml","form_type":"4"}},{"id":1607836,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-02T00:14:43.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met."}],"balance_after":78500,"derivative":{"exercise_price":1.27,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0000905148-24-000848","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000848/form4.xml","form_type":"4"}},{"id":1607835,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-02T00:14:43.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted an option with a performance-based condition with respect to 93,750 shares of the issuer's common stock on December 8, 2022. Thus, the exercise price of this option is $0.8965 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met."}],"balance_after":93750,"derivative":{"exercise_price":0.8965,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0000905148-24-000848","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000848/form4.xml","form_type":"4"}},{"id":1671204,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-01-26T02:17:36.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":157000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period."}],"balance_after":157000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":157000},"source":{"system":"sec-edgar","filing":"0000905148-24-000309","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000309/form4.xml","form_type":"4"}},{"id":1671203,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"officer":true,"officer_title":"EVP, GC, CCO & Corp Sec"}}],"security":"Common Stock","published_at":"2024-01-26T02:17:36.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":209000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 1, 2024, with the first annual vest occurring on February 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":214000,"source":{"system":"sec-edgar","filing":"0000905148-24-000309","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000309/form4.xml","form_type":"4"}},{"id":4495955,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Compliance Officer"}}],"security":"Ordinary Shares","published_at":"2017-01-06T23:06:58.000Z","date":"2017-01-04","kind":"tax_withholding","acquired":false,"shares":242,"price":53.19,"value":12871.98,"ownership":{"direct":true},"balance_after":6462,"source":{"system":"sec-edgar","filing":"0000950138-17-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000047/edgar.xml","form_type":"4"}},{"id":4501538,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":2424,"kind":"person","name":"Furey Raymond J.","position":1,"cik":"0001577899","reported_name":"Furey Raymond J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Compliance Officer"}}],"security":"Ordinary Shares","published_at":"2017-01-05T02:17:06.000Z","date":"2017-01-02","kind":"tax_withholding","acquired":false,"shares":102,"price":49.82,"value":5081.64,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 569 shares acquired between January 7, 2016 and September 30, 2016 under the Mallinckrodt employee stock purchase plan."}],"balance_after":6704,"source":{"system":"sec-edgar","filing":"0000950138-17-000024","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000024/edgar.xml","form_type":"4"}}]}